Advances in Non-Viral Gene Delivery Systems for Lung Cancer
Non-viral gene delivery systems have gained significant attention as safer alternatives to viral vectors for lung cancer transfection. These methods utilize synthetic or natural materials to transport nucleic acids into cells, minimizing immunogenicity, insertional mutagenesis, and manufacturing complexities associated with viral vectors.
Lipid-based nanoparticles remain the most extensively studied non-viral carriers, offering tunable properties for optimizing stability, cellular uptake, and endosomal escape. Innovations in lipid composition and surface modifications enhance targeting to lung cancer cells and improve biocompatibility. Polymeric nanoparticles, constructed from biodegradable materials such as chitosan or PLGA, provide additional versatility in cargo loading and controlled release.
Physical methods like electroporation and microinjection continue to play vital roles in lung cancer gene delivery, especially in vitro. However, their invasive nature and scalability challenges limit their therapeutic applications. Emerging techniques, such as ultrasound-mediated sonoporation and magnetofection, are being explored to improve gene transfer efficiency non-invasively.
Combination strategies that integrate non-viral carriers with targeting ligands, stimuli-responsive elements, or co-delivered adjuvants show promise in overcoming biological barriers within the lung tumor microenvironment.
While challenges persist, including optimizing delivery efficiency and ensuring selective targeting, advances in non-viral gene delivery hold great potential for lung cancer research and therapy development, providing safer, flexible platforms for genetic manipulation.
References: Altogen.com Altogenlabs.com